Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_869_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
31.08.2026
Размер:
36 Мб
Скачать
452
J. Leroy et al.
endoscopic microsurgery in rectal cancer. Chirurg. 1989;60(12):901–4. [Article in German]. PMID:
2695299.
14. Kim EK, Sheetz KH, Bonn J, DeRoo S, Lee C, Stein I, et al. A statewide colectomy experience: the role of full bowel preparation in preventing surgical site infection. Ann Surg. 2014;259:310–4.
15. Lange MM, Buunen M, van de Velde CJH, etal. Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review. Dis Colon Rectum. 2008;51(7):1139–45. https://doi.org/10.1007/s10350-
008-9328-y. Epub 2008 May 16. Review. PMID:
18483828.
16. Kanemitsu Y, Hirai T, Komor K, et al. Survival benet of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery. Br J Surg. 2006;93:609–15. https://doi.org/10.1007/
DCR.0b013e3181cf7609. PMID: 20389212.
17. Pezim ME, Nicholls RJ.Survival after high or low liga­tion of the inferiormesenteric artery during curative sur­gery for rectal cancer. Ann Surg. 1984;200(6):729–33. PMID: 6508403.
18. Hideo Y. Laparoscopic colectomy using retro­peritoneal approach method. Gastroenterol Surg. 2004;27(6):861–9.
19. Occelli B, Narducci F, Lanvin D, Coste E, Legoupils E, Castelain B, Querleu D.Comparison of transperi­toneal versus extraperitoneal laparoscopic para-aortic lymphadenectomy: randomized experimental study. Ann Chir. 2000;125(1):9–17. [Article in French].
20. Narducci F, Occelli B, Lanvin D, Vinatier D, Leblanc E, Querleu D. Endoscopic para-aortic dissection by the extraperitoneal approach: clinical study of 37 patients. Gynecol Obstet Fertil. 2000;28(2):108–14. [Article in French].
21. Penna M, Hompes R, Arnold S, Wynn G, Austin R, Warusavitarne J, Moran B, Hanna GB, Mortensen NJ, Tekkis PP, TaTME Registry Collaborative. Transanal total mesorectal excision: international registry results of the rst 720 cases. Ann Surg. 2017;266(1):111–7.
https://doi.org/10.1097/SLA.0000000000001948.
PMID: 27735827.
22. Tuech JJ, Karoui M, Lelong B, De Chaisemartin C, Bridoux V, Manceau G, et al. A step toward NOTES total mesorectal excision for rectal cancer: endoscopic transanal proctectomy. Ann Surg. 2015;261(2):228–
33. https://doi.org/10.1097/SLA.0000000000000994.
23. Wolthuis AM, de Buck van Overstraeten A, D’Hoore A.Dynamic article: transanal rectal excision: a pilot study. Dis Colon Rectum. 2014;57(1):105–9. https://
doi.org/10.3748/wjg.v20.i36.12981. Review. PMID:
25278692.
24. Velthuis S, Nieuwenhuis DH, Ruijter TE, Cuesta MA, Bonjer HJ, Sietses C. Transanal versus traditional laparoscopic total mesorectal excision for rectal car­cinoma. Surg Endosc. 2014;28(12):3494–9. https://
doi.org/10.1007/s00464-014-3636-1. Epub 2014 Jun
28. PMID: 24972923.
25. Delgado S, Fernandez M, Lacy AM.Laparoscopic­assisted total mesorectal resection through the trans-
anal route. Cir Esp. 2014;92(Suppl 1):21–9. https://
doi.org/10.1016/S0009-739X(14)70005-3. PMID:
24842688.
26. Atallah S, Martin-Perez B, Albert M, deBeche-Adams T, Nassif G, Hunter L, etal. Transanal minimally inva­sive surgery for total mesorectal excision (TAMIS­TME): results and experience with the rst 20 patients undergoing curative-intent rectal cancer surgery at a single institution. Tech Coloproctol. 2014;18(5):473–
80. https://doi.org/10.1007/s10151-013-1095-7. Epub 2013 Nov 23. PMID: 24272607.
27. Velthuis S, van den Boezem PB, van der Peet DL, Cuesta MA, Sietses C.Feasibility study of transanal total mesorectal excision. Br J Surg 2013;100(6):828–
31. discussion 31. doi: https://doi.org/10.1002/
bjs.9069. Epub 2013 Feb 25. PMID: 23440708.
28. Sylla P, Bordeianou LG, Berger D, Han KS, Lauwers GY, Sahani DV, et al. A pilot study of natural ori­ce transanal endoscopic total mesorectal exci­sion with laparoscopic assistance for rectal cancer. Surg Endosc. 2013;27(9):3396–405. https://doi.
org/10.1007/s00464-013-2922-7. Epub 2013 Apr 10.
PMID: 23572214.
29. Rouanet P, Mourregot A, Azar CC, Carrere S, Gutowski M, Quenet F, et al. Transanal endoscopic proctectomy: an innovative procedure for difcult resection of rectal tumors in men with narrow pel­vis. Dis Colon Rectum. 2013;56(4):408–15. https://
doi.org/10.1097/DCR.0b013e3182756fa0. PMID:
23478607.
30. Lacy AM, Rattner DW, Adelsdorfer C, Tasende MM, Fernandez M, Delgado S, et al. Transanal natural orice transluminal endoscopic surgery (NOTES) rectal resection: “down-to-up” total mesorectal exci­sion (TME)–short-term outcomes in the rst 20 cases. Surg Endosc. 2013;27(9):3165–72. https://doi.
org/10.1007/s00464-013-2872-0. Epub 2013 Mar 22.
PMID: 23519489.
31. Chouillard E, Chahine E, Khoury G, Vinson-Bonnet B, Gumbs A, Azoulay D, et al. NOTES total meso­rectal excision (TME) for patients with rectal neo­plasia: a preliminary experience. Surg Endosc. 2014;28(11):3150–7. https://doi.org/10.1007/s00464-
014-3573-z. Epub 2014 May 31. PMID: 24879139.
32. Zhang H, Zhang YS, Jin XW, Li MZ, Fan JS, Yang ZH. Transanal single-port laparoscopic total meso­rectal excision in the treatment of rectal cancer. Tech Coloproctol. 2013;17(1):117–23. https://doi.
org/10.1007/s10151-012-0882-x. Epub 2012 Aug 31.
PMID: 22936590.
33. Park SJ, Sohn DK, Chang TY, Jung Y, Kim HJ, Kim YI, Chun HK, Korea Natural Orice Transluminal Endoscopic Surgery (K-NOTES) Study Group. Transanal natural orice transluminal endoscopic surgery total mesorectal excision in animal models: endoscopic inferior mesenteric artery dissection made easier by a retroperitoneal approach. Ann Surg Treat Res. 2014;87(1):1–4.
34. Marks JH, Lopez-Acevedo N, Krishnan B, Johnson MN, Montenegro GA, Marks GJ.True NOTES TME
43 Pure NOTES Transanal TME
453
resection with splenic exure release, high ligation of IMA, and side-to-end hand-sewn coloanal anastomo­sis. Surg Endosc. 2016;30(10):4626–31. https://doi.
org/10.1007/s00464-015-4731-7. Epub 2016 Jan 28.
PMID: 26823054.
35. Atallah SB, DuBose AC, Burke JP, Nassif G, deBeche-Adams T, Frering T, Albert MR, Monson JRT. Uptake of transanal total mesorectal excision in North America: initial assessment of a structured training program and the experience of delegate sur­geons. Dis Colon Rectum. 2017;60(10):1023–31.
https://doi.org/10.1097/DCR.0000000000000823.
36. Penna M, Whiteford M, Hompes R, Sylla P.Developing and assessing a cadaveric training model for transanal total mesorectal excision: initial experience in the UK and USA.Color Dis. 2017;19(5):476–84. https://doi.
org/10.1111/codi.13525. PMID: 27647728.
37. Francis N, Penna M, Mackenzie H, Carter F, Hompes R, International TaTME Educational Collaborative Group. Consensus on structured training curriculum for transanal total mesorectal excision (TaTME). Surg Endosc. 2017;31(7):2711–9. https://doi.org/10.1007/
s00464-017-5562-5. Epub 2017 May 1. PMID:
28462478.
Totally Robotic taTME: Experiences andChallenges toDate
MarcosGómezRuiz
44

Introduction

For the last two decades, total mesorectal exci­sion (TME) has been transforming the outcomes of rectal cancer surgery and is a technique which holds great promise [1].
As in any other oncological surgical tech­nique, TME surgical quality has a direct impact on local control and survival [2, 3]. In the patho­logical assessment of rectal cancer specimens, the circumferential radial margin (CRM) and the plane of surgery achieved are clear independent predictors of local recurrence [4]. At the same time, not only oncological but also functional outcomes have a signicant impact on patients’ postoperative quality of life. These results are not always favorable with current surgical techniques for rectal cancer treatment.
Open approach for rectal cancer treatment is the standard of care in most of the centers in the world. This approach is associated with poor postopera­tive outcomes in terms of patient recovery, pain, lengths of stay, and blood loss [5]. Laparoscopic colorectal surgery started 27 years ago [6] to improve the clinical, oncological, and functional outcomes that open surgery can provide in rectal
M. G. Ruiz (*) Hospital Universitario Marqués de Valdecilla, IDIVAL, Servicio de Cirugía General y Aparato Digestivo, Unidad de Cirugía Colorrectal, Santander, Spain e-mail: marcos.gomez@scsalud.es
cancer surgery. Laparoscopic rectal resection has shown clear advantages in short- term clinical out­comes [7, 8]. However, ALaCaRT and ACOSOG Z6051 trials further questioned the oncologic equivalence of the laparoscopic approach for rectal cancer. These trials failed to establish the oncologi­cal non inferiority of laparoscopy compared to open rectal cancer surgery [9, 10].
Robotic-assisted surgery was introduced at the dawn of the new millennium. This new technique appeared to present clear advantages over lapa­roscopy, with improved stereoscopic visualiza­tion, endowristed instrumentation, and superior surgeon ergonomics that diminish fatigue, partic­ularly for long and complex operations. Robotic­assisted surgery has been shown (in single- center series and some meta-analysis reports) to be asso­ciated with lower conversion rates, better TME quality, lower positive CRM rates, and earlier recovery of genitourinary functions [11]. Robotic surgery is generally easier to learn than laparo­scopic surgery, improving the probability of auto­nomic nerve preservation and genitourinary function recovery [12, 13]. Furthermore, in very complex rectal cancer, TME procedures such as intersphincteric dissections and transabdominal transections of the levator muscle, the robotic approach is associated with increased perfor­mance and safety compared to laparoscopic sur­gery [14, 15]. Despite these encouraging data, the ROLARR trial failed to establish a clear benet of robotic-assisted approach when comparing
© Springer Nature Switzerland AG 2019 S. Atallah (ed.), Transanal Minimally Invasive Surgery (TAMIS) and Transanal Total Mesorectal Excision (taTME), https://doi.org/10.1007/978-3-030-11572-2_44
455
456
M. G. Ruiz
postoperative outcomes with the laparoscopic approach [16]. Furthermore, the cost of robotic surgery must also be addressed before it can become the new standard treatment.
There is a close relationship about the rate of CRM involvement and the local recurrence. The impact of robotic-assisted TME on CRM involve­ment, however, remains controversial. Several studies report no signicant differences in CRM involvement as compared to laparoscopic­assisted TME [17, 18]. Nonetheless, a few retro­spective case-matched studies found signicantly decreased CRM involvement after robotic­assisted TME [19, 20]. Currently, there is limited literature dedicated to assessing the quality of TME in robotic-assisted surgery [20]. Reviewing the current literature on CRM, this is reported as a discrete variable dened as <1 mm [21] or 2 mm [19] rather than continuous variable in mm. Of course, if the tumor (or a positive node) extends to the CRM, this represents not only a positive margin but implies an R1 resection.
Araujo etal. [22] published a large review of the literature in which they reported the oncologic outcomes after robotically performed tumor-spe­cic mesorectal excision for rectal cancer includ­ing 1776 patients from 32 reports. The authors reported no signicant differences on pathologi­cal data such as number of lymph nodes yield and rate of positive CRM. In these series, the mean number of harvested lymph nodes ranged between
10.3 and 20, whereas the total CRM positivity varied between 0% and 7.5%. Nevertheless, although certain heterogeneity among studies is to be acknowledged, a trend toward lower CRM involvement after robotic resections was noted in comparison to both laparoscopy and open stan­dard surgery. It should be noted that, for rectal cancer surgery, the quality of the TME dissection and the CRM status are far more important vari­ables than the number of lymph nodes harvested.

Transanal Total Mesorectal Excision

Transanal total mesorectal excision (taTME) was developed to overcome the inherent limits of abdominal approaches, also known as “anterior”
approaches, either open, laparoscopic, or, more recently, robotic. Indeed, a laparoscopic low ante­rior resection (LAR) remains particularly chal­lenging in adverse anatomical situations, such as male patients with a narrow pelvis, visceral obe­sity, prostatic hypertrophy, or neoadjuvant chemo­radiotherapy. Exposure, rectal dissection, and
challenging in these conditions. Starting with dis­section from the perineum seems to offer advan­tages, by avoiding distal cross- stapling in a narrow pelvis. The use of laparoscopic staplers in this situ­ation is difcult as multiple staple rings across the low rectum increase potential for anastomotic leak [23]. The potential anastomotic benets of a transanal approach have been challenged by the recent publication of the International Registry in which the number of low anastomosis and anasto­motic leak rate was concerning [24, 25].
The concept is that a bottom-up (caudal to ceph­alad) or retrograde dissection technique may pro­vide the surgeon some advantages including the ability to directly visualize and choose the distal resection margin. A transanal purse-string suture below the tumor ensures that an adequate oncologi­cal distal margin will be achieved; it also allows using the pneumatic insufation of the mesorectal plane to facilitate rectal dissection. The optimal close visualization of the mesorectal dissection plane might reduce injury to surrounding structures such as the vagina, prostate, pelvic nerves, and pel­vic vessels. Importantly, from the taTME vantage point, conicts with the adjacent intra-abdominal pelvic structures and viscera are avoided, as they no longer need to be retracted cephalad for rectal mobilization in this unique setting.
The technique itself demands an understand­ing of pelvic anatomy as well as comfort with currently available surgical equipment including the access platforms and insufation systems that make this approach possible. These concepts have been challenged by the reported urethral injuries and recent publications in which taTME had a higher positive distal resection margin (DRM) when compared with a robotic low ante­rior resection [26].
After M.Whiteford rst described taTME in a cadaveric model in 2007, P. Sylla and A. Lacy
44 Totally Robotic taTME: Experiences andChallenges toDate
457
described the rst successful clinical use of taTME in 2010in a patient with a rectal carcinoma of the middle third [27]. Since 2010, TaTME has had an important impact worldwide, and there has been a signicant increase in the number of publications related with taTME over the past 8years [28]. This concept can be further supported by the fact that national training programs are being developed to ensure that there is safe introduction of taTME across Europe, North America, as well as parts of South America (such as Brazil), and Southeast Asia.
Several cohort series have been published regarding hybrid endoscopic taTME [2932]. These series suggest that taTME is feasible and safe regarding short-term outcomes and that it delivers high-quality TME specimens in selected patients. Wolthuis etal. [33] reviewed 20 stud­ies where 323 patients were included. Most studies were single-arm prospective studies with fewer than 100 patients. Multiple transanal access platforms were used, and the laparo­scopic approach was either a multi- or single­port platform. The procedure was initiated either by transanal or transabdominal. When a simul­taneous approach with two operating surgeons was chosen (Cecil approach), the operative time was signicantly reduced.
This review clearly demonstrated that taTME is currently performed in a non-standardized way, which reects surgeons exploring the tech­nical boundaries of ultralow rectal cancer.
The published series that excluded T4 tumors have demonstrated a promising CRM involve­ment of 0–5.4% [33]. The largest series, including 140 patients, reported CRM involvement of 6.4% [34]; however, T4 tumors were not excluded, and all patients with involvement of CRM were cor­rectly predicted by MRI [35]. Short-term morbid­ity and oncological results were comparable to other laparoscopic TME series [33].
In the largest published taTME series to date [33], the CRM positivity rates range from 2.5% to 6.4%. When taTME and robotic LAR have been compared in retrospective multicenter stud­ies, similar CRM positivity rates have been found [26]. Long-term follow-up is necessary to assess more accurately these data and validate onco­logic outcomes.
The signicant rate of taTME-related urethral injury occurs at the posterior wall of the pre­prostatic urethra in male patients with a distal anterior rectal cancer (within 3 cm of the anal verge). Atallah [36] has observed in his North American Training Program on taTME that approximately 20% of cadaveric trainees (all with considerable rectal cancer experience) will inadvertently mobilize the prostate and enter the incorrect plane, underscoring the importance of adequate training in this technique, which approaches the rectum from an unfamiliar van­tage point. Other cautionary points during taTME include meticulous attention to the autonomic nerve plexi [37] and other anatomic structures detailed in other chapters.
With appropriate training, taTME can be con­sidered a real advancement in the surgical man­agement of rectal cancer surgery. However, it is yet to be seen as to whether or not it will become a real scientically proven advantage [38, 39]. Randomized trials have been constructed to chal­lenge this issue. There is already an International taTME Registry in place with more than 1500 cases reported so far [24, 25]. In Europe, the GRECCAR 11 trial [40], COLOR III trial [41], and in the near future RESET trial have been designed and are being developed to compare taTME with other existing anterior approaches. In particular, COLOR III and GRECCAR 11 are prospective, multicenter, randomized trials planned to compare taTME with laparoscopic TME.It will take years before robust data will be available. During this period, care must be taken before proposing taTME outside of expert centers.

Robotic Transanal Total Mesorectal Excision (Robotic taTME)

Clinical experience of robotic taTME started in 2013 when Atallah etal. [42] reported the rst clinical case in a patient with familial adenoma­tous polyposis and two synchronic tumors. Our group published our robotic taTME experience in a cadaver model [43] using the PAT plat­form (Developia-IDIVAL, Santander, Spain),
458
M. G. Ruiz
a self- designed platform, and the 80-mm Gel­POINT gel cap (Applied Medical, Rancho Santa Margarita, CA, USA). On August 2013, we per­formed the rst clinical case in Europe [44]. To date, very few publications are available on robotic taTME, and all of these only report early experi­ences [45, 46] or short series of cases concluding that this technique is feasible and safe [47].
Atallah etal. published their initial experience [48] with three patients that underwent curative- intent robotic taTME using the da Vinci Si Surgical System. They performed the abdominal phase of the procedure with a laparoscopic approach and the taTME with robotic assistance. They used a commercially available transanal minimally inva­sive surgery (TAMIS) port (GelPOINT path trans­anal access platform) to dock and interface with the robotic arms transanally.
In these three patients, the average age was 45years (range 26–59) with mean BMI of 32kg/ m2 (range 21–38.5). The average tumor size was
2.5cm. All lesions were in the distal 5cm of the rectum. Mean operative time was 376min. DRM and CRM were free of tumor, with the closest DRM being 1 cm. The resection quality of the mesorectal envelope was graded for complete­ness by an independent GI pathologist and was found to be near complete in two cases and com­pletely intact in one case.
We reported the results of our pilot study with our initial ve cases of complete robotic taTME [49]. We used a “transanal access port” procto- scope (PAT, Developia-IDIVAL, Santander, Spain). PAT was inserted transanally, and a GelPOINT gel cap was used to occlude the proc­toscope and for trocar placement. This platform (which is essentially a hybrid between TEO and TAMIS) allows for optimal lateral docking of the da Vinci Si Surgical System (Intuitive Surgical, Sunnyvale, CA, USA) with unencumbered move­ments of the robotic arms. All patients underwent a dual-docking procedure with robotic-assisted multiport laparoscopic left colon mobilization, robotic-assisted taTME, ultralow mechanical colorectal or handsewn coloanal anastomosis, and a diverting loop ileostomy. Four patients with stage III disease received preoperative long­course chemoradiation before surgery. In all
cases, pathological examination of the TME spec­imens showed complete mesorectal excision with negative proximal, distal, and circumferential margins. These preliminary results allowed us to conclude that this technique is feasible, with good pathological results and postoperative outcomes.
Currently, Li-JenKuo etal. [50] have published the largest robotic taTME.Left colon mobiliza­tion was performed with a single-site robotic approach. In this series, 15 patients underwent robotic taTME, with two conversions. Morbidity included an injury to the ureter, and one patient presented a Clavien IIIb complication because of a small bowel obstruction.
Totally Robotic tATME: TheSantander Experience
Surgical Technique
The following section describes the technique used for totally robotic taTME, utilizing the da Vinci Si Surgical System with dual-docking.
With the patient under general anesthesia, a urinary catheter is inserted, and the patient is placed in the lithotomy position with the use of stirrups. Digital examination and rigid proctos­copy are performed to conrm the tumor location. Abdominal access is achieved via Veress needle, which is inserted in the left upper quadrant and the abdomen, and CO2 insufation commences to an average pressure of 12mmHg. Robotic 8-mm trocars are next inserted in the right upper quad­rant (12–15mm and 8mm), right lower quadrant (two 8-mm trocars), and periumbilical region (12–15mm). The patient is positioned in a right tilt, and the peritoneal cavity is rst inspected through a standard laparoscope. After conrming the absence of signicant intra- abdominal adhe­sions and no evidence of distal tumor extension or cacinomatosis, the da Vinci Si robotic cart is docked from the patient’s left side (Fig. 44.1). Monopolar curved scissors are placed in Arm 1, a fenestrated bipolar grasper is placed in Arm 2, and a double-fenestrated grasper is used in Arm 3. A 30° 12-mm endoscope is employed. The splenic exure is rst taken down with dissection and
44 Totally Robotic taTME: Experiences andChallenges toDate
459
Fig. 44.1 Da Vinci Si System docked from the left lateral side of the patient
division of the inferior mesenteric vein and artery at their root. The descending and sigmoid colon are then mobilized, nishing the dissection at the sacral promontory once the ureter and iliac ves­sels are identied. The robotic surgical system is next undocked, and the patient is repositioned in the Trendelenburg position with a slight right tilt for the next phase of the operation.
Partial intersphincteric resection can be per­formed for tumors located at 3cm from the anal verge. A Lone Star retractor (Lone Star Medical Products Inc., Houston, TX) or a PPH anoscope (Ethicon Endosurgery, Cincinnati, OH) is posi­tioned, and the mucosa and internal sphincter muscle are dissected circumferentially beginning at least 1cm below the distal margin of the tumor. Intersphincteric dissection is extended cephalad for 1–2 cm, and a purse-string suture is then placed to occlude the rectum below the tumor (Fig.44.2).
Following rectal occlusion, a “transanal access port” proctoscope (Fig.44.3) is inserted transa­nally, and a 80-mm GelPOINT gel cap is adapted to this custom-made platform. The robotic tro­cars are then directly introduced through the gel cap for robotic taTME.
A 12-mm or an 8.5-mm trocar can be used for the optical port. Two 8-mm trocar ports are inserted with a distance of at least 4cm between robotic instruments, and an accessory 12-mm tro­car is inserted for the assistant port. The da Vinci robotic cart is next docked over the left hip of the
Fig. 44.2 Anal exposure for ISR resection or purse­string suture
Fig. 44.3 Transanal access port proctoscope. (Developia­IDIVAL, Santander, Spain)
patient. The fenestrated bipolar grasper is then placed in Arm 1 on the left, while monopolar scissors are placed in Arm 2 on the right, and a 30° endoscope is placed through the 12-mm tro­car. The assistant trocar is used primarily to assist in tissue countertraction or to apply suction or irrigation (Fig. 44.4). If available, an AirSEAL System (Conmed, Utica, NY, USA) 5-mm or 8-mm valveless tocar can be used for the assis­tant, thereby stabilizing the pneumatics, as dis­cussed elsewhere.
When partial intersphincteric resection had not previously been done (patients with tumors located higher than 3cm from anal verge), the rectum is insufated with CO2 to a pressure of 8 to 10mmHg. The rectal mucosa is then scored
460
Fig. 44.4 Da Vinci Si System docked transanally using PAT proctoscope
circumferentially with monopolar cautery begin­ning distal to the purse-string and followed by full-thickness rectal dissection. After rectal wall division, the pelvic space around the remnant anal canal is insufated to facilitate pelvic dis­section and robotic taTME.Anteriorly, the rec­tum is dissected from the posterior vagina or prostate following Denonvilliers fascia until the peritoneal reection is reached and divided. Posterior and lateral mesorectal dissection is performed by using a transanal approach with laparoscopic assistance.
Following adequate colonic mobilization, the rectum can be grasped and exteriorized transa­nally under laparoscopic visualization or through the ileostomy site. An Alexis wound retractor (Applied Medical Inc., Rancho Santa Margarita, CA) can be utilized. A handsewn end-to-end coloanal anastomosis or mechanical end-to-end colorectal anastomosis is performed, depending on case specics and tumor height. A diverting loop ileostomy is next created, and a pelvic drain can be placed intra-abdominally.
Clinical Outcomes
Thirty-seven consecutive totally taTME robotic cases have been performed in our unit between 2013 and 2017. Conversion was required in one case (2.70%). Transanal specimen extraction was performed in 56.2% of the patients, and through
M. G. Ruiz
Table 44.1 Clavien-Dindo Complication Distribution
Clavien-Dindo Complications
Number Rate (%) No complications 28 75.7 I 3 8.1 II 3 8.1 IIIb 2 5.4 IV 1 2.7 Total 37 100.0
the stoma site in 37.8%, Pfannenstiel incision was used in 6% of the patients. Clavien distribu­tion is shown in Table44.1. Mean hospital stay was 7.54 +/5.258 days (Table 44.2.). Three patients presented anastomotic leak (8.1%), one of them Grade C.
TNM and UICC distribution of the patients is described in Tables 44.3 and 44.4. The median harvested lymph nodes were 12.6. TME quality assessed by pathologist was complete in
94.6% and almost complete in two cases: 5.4%. DRM and CRM were negative in all cases. Mean tumor height from anal verge was 5.33cm (2–9cm). In the follow-up, no patient presented local recurrence.
When analyzing our results and comparing them with the ones published in the International taTME Registry [25], our lower rate of visceral injuries and rectal perforations supports this potential benet, even though our experience is limited to 37 cases, which is still under the learning curve for taTME [51]. The goal is to achieve the best quality of surgery to obtain the best clinical, oncological, and functional out­comes. To do this, the key points are to obtain an excellent vision and information of the surgical anatomy with the assistance of surgical instruments.
TaTME may provide better results because it improves the vision of the surgical eld. The robotic systems facilitate the surgical perfor­mance with the endowristed instrumentation. In addition, they can optimize vision and informa­tion of the surgical eld with the 3D immersive view and with the potential use of augmented reality. The use of stereotactic navigation in the pelvic surgery can be another important step to facilitate the safety as well as oncological quality
44 Totally Robotic taTME: Experiences andChallenges toDate
Table 44.2 Mean hospital stay
Hospital stay
N Minimum Maximum Mean Std. deviation
Hospital stay 37 4 30 7.54 5258
461
Table 44.3 TNM distribution
Rate %
T 0 8 21.6
1 8 21.6 2 9 24.3
3 12 32.4 Total 37 100.0 N N0 32 86.5
N1a 5 13.5 Total 37 100.0
Table 44.4 UICC distribution
Rate %
UICC 0 3 8.1
I 13 35.1 IIA 9 24.3 IIIA 1 2.7 IIIB 6 16.2 Complete response 5 13.5 Total 37 100.0
through improved precision [5254]. The robotic and fully computerized systems can facilitate the implementation of this technology [55].

Future: New Robotics Platforms

The widespread of the clinical use of the robotic rectal surgery is being limited mainly by the eco­nomic costs and access to clinical experience in sufcient number.
Today, the technological progression is expo­nential. Robotic rectal surgery started less than 10years ago with the da Vinci Surgical System, and in this period four different systems have pro­gressively been used: S, Si, X, and Xi. SP plat­form has recently achieved the US Food and Drug Administration (FDA) approval for its use in uro­logical procedures and will probably achieve the same approval for colorectal procedures within the next 2years. After initial evaluation in cadaver
model [56], preliminary results of its clinical use in three taTME procedures performed by Simon Ng, MD at the Chinese University Hong Kong (Hong Kong), seem promising.
A new wave of robotic platforms specically designed for single-port and natural orice sur­gery is currently under development and evalua­tion. The main advantage of these systems is the addition of exible effector arms and/or cameras which can be manipulated in part, or completely, by a master-slave, computer-assisted system [57]. Such systems could change our approach to complex surgical or endoscopical procedures, unique to the eld of colorectal surgery, but they rst require careful assessment and validation.
In 2017, the Flex® Robotic System and Flex® Colorectal (CR) Drive (MedRobotics, Corp. Raynham, MA, USA), a semi-robotic apparatus for colorectal surgery specically indicated for transanal endoluminal applications, as well as more radical resection (i.e., taTME), was approved by the US Food and Drug Administration (FDA). This platform has already been used in cadaver model and is currently under evaluation in a clinical trial [58]. The exible effector arms measure only 3.5mm, but are not robotic assisted, which is a limitation of the current technology. Other limitations include suturing at ranges beyond 15cm, needle delivery, and retrieval, and the process of suturing itself can sometimes be encumbered by the Flex® Robot’s convolution throughout the sigmoidal bends.
Other single incision platforms such as the SPORT ® Surgical System (Titan Medical, Toronto, Canada) [59] or the multi-trocar platforms like the expected robotic systems from Cambridge Medical Robotics, Medtronic, Medicaroid, or Verb Surgical are also in the pipeline for robotic taTME.The latter, a joint venture between Google and Johnson & Johnson, hopes to digitize surgery, thereby providing computer- assisted technology that can ultimately improve surgical precision.
462
M. G. Ruiz

References

1. Heald RJ, Husband EM, Ryall RD.The mesorectum in rectal cancer surgery - the clue to pelvic recur­rence? Br J Surg. 1982;69:613–6.
2. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O’Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ, Sebag­Monteore D, Investigators MCN-CCT, Group NCCS. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal can­cer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet. 2009;373:821–8.
3. Martling A, Singnomklao T, Holm T, Rutqvist LE, Cedermark B.Prognostic signicance of both surgi­cal and pathological assessment of curative resection for rectal cancer. Br J Surg. 2004;91:1040–5.
4. Nikberg M, Kindler C, Chabok A, Letocha H, Shetye J, Smedh K. Circumferential resection margin as a prognostic marker in the modern multidisciplinary management of rectal cancer. Dis Colon Rectum. 2015;58:275–82.
5. Pahlman L, Bohe M, Cedermark B, Dahlberg M, Lindmark G, Sjodahl R, etal. The Swedish rectal can­cer registry. Br J Surg. 2007;94(10):1285–92.
6. Jacobs M, Verdeja JC, Goldstein HS.Minimally inva­sive colon resection (laparoscopic colectomy). Surg Laparosc Endosc. 1991;1(3):144–50.
7. Arezzo A, Passera R, Scozzari G, Verra M, Morino M.Laparoscopy for rectal cancer reduces short-term mortality and morbidity: results of a systematic review and meta-analysis. Surg Endosc. 2013;27:1485–502.
8. Arezzo A, Passera R, Scozzari G, Verra M, Morino M. Laparoscopy for extraperitoneal rectal cancer reduces short-term morbidity: results of a system­atic review and meta-analysis. United European Gastroenterol J. 2013;1:32–47.
9. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, Peters WR Jr, Maun D, Chang G, Herline A, Fichera A, Mutch M, Wexner S, Whiteford M, Marks J, Birnbaum E, Margolin D, Larson D, Marcello P, Mitchell Posner M, Read T, Monson J, Wren SM, Pisters PWT, Nelson H.Effect of laparoscopic- assisted resection vs open resection of stage II or III rectal cancer on pathologic out­comes. The ACOSOG Z6051 randomized clinical trial. JAMA. 2015;314(13):1346–55.
10. Stevenson ARL, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, Davies L, Wilson K, Hague W, Simes J, for the ALaCaRT Investigators. Effect of laparo­scopic-assisted resection vs open resection on pathologi­cal outcomes in rectal cancer. The ALaCaRT randomized clinical trial. JAMA. 2015;314(13):1356–63.
11. Trastulli S, F E CR, Cavaliere D, Avenia N, Sciannameo F, Gullà N, Noya G, Boselli C.Robotic resection compared with laparoscopic rectal resection for cancer: systematic review and meta-analysis of short-term outcome. Color Dis. 2012;14(4):e134–56.
12. D’Annibale A, P G, Monsellato I, Pende V, Lucandri G, Mazzocchi P, Alfano G.Total mesorectal excision: a comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. Surg Endosc. 2013;27(6):1887–95.
13. Luca F, Valvo M, Ghezzi TL, Zuccaro M, Cenciarelli S, Trovato C, Sonzogni A, Bif R.Impact of robotic surgery on sexual and urinary functions after fully robotic nerve-sparing total mesorectal excision for rectal cancer. Ann Surg. 2013;257:672–8.
14. Marecik SJ, Zawadzki M, Desouza AL, Park JJ, Abcarian H, Prasad LM.Robotic cylindrical abdomi­noperineal resection with transabdominal levator tran­section. Dis Colon Rectum. 2011;54:1320–5.
15. Park SY, Choi GS, Park JS, Kim HJ, Ryuk JP.Short­term clinical outcome of robot-assisted intersphinc­teric resection for low rectal cancer: a retrospective comparison with conventional laparoscopy. Surg Endosc. 2013;27:48–55.
16. Jayne D, Pigazzi A, Marshall H, Croft J, Corrigan N, Copeland J, Quirke P, West N, Rautio T, Thomassen N, Tilney H, Gudgeon M, Bianchi PP, Edlin R, Hulme C, Brown J.Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA. 2017;318(16):1569–80.
17. Saklani AP, L D HH, Min BS, Baik SH, Lee KY, Kim NK.Robotic versus laparoscopic surgery for mid-low rectal cancer after neoadjuvant chemoradiation ther­apy: comparison of oncologic outcomes. Int J Color Dis. 2013;28(12):1689–98.
18. Fernandez R, A D, Li LT, Orcutt ST, Balentine CJ, Awad SA, Berger DH, Albo DA, Artinyan A.Laparoscopic versus robotic rectal resection for rectal cancer in a veteran population. Am J Surg. 2013;206(4):509–17.
19. Park JS, C G, Lim KH, Jang YS, Jun SH. Robotic­assisted versus laparoscopic surgery for low rec­tal cancer: case-matched analysis of short-term outcomes. Ann Surg Oncol. 2010;17(12):3195–202.
20. Barnajian M, Pettet D, Kazi E, Foppa C, Bergamaschi R.Quality of total mesorectal excision and depth of circumferential resection margin in rectal cancer: a matched comparison of rst 20 robotic cases. Color Dis. 2014;16(8):603–9.
21. Bianchi PP, C C, Locatelli A, Spinoglio G, Zampino MG, Sonzogni A, Crosta C, Andreoni B. Robotic versus laparoscopic total mesorectal excision for rectal cancer: a comparative analysis of oncologi­cal safety and short-term outcomes. Surg Endosc. 2010;24(11):2888–94.
22. Araujo SEA, Seid VE, Klajner S. Robotic sur­gery for rectal cancer: current immediate clinical and oncological outcomes. World J Gastroenterol. 2014;20(39):14359–70.
23. Ito M, Sugito M, Kobayashi A, Nishizawa Y, Tsunoda Y, Saito N.Relationship between multiple numbers of stapler rings during rectal division and anastomotic leakage after laparoscopic rectal resection. Int J Color Dis. 2008;23:703–7.